<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Artesunate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Artesunate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Artesunate: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="17088" href="/d/html/17088.html" rel="external">see "Artesunate: Drug information"</a> and <a class="drug drug_patient" data-topicid="128392" href="/d/html/128392.html" rel="external">see "Artesunate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F29531509"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antimalarial Agent</span>;</li>
<li>
<span class="list-set-name">Artemisinin Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F13321414"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="907db476-c453-431b-8e3f-050c1461baaf">Malaria, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria (severe), treatment:</b> Limited data available: <b>Note: </b>Patients with <i>Plasmodium vivax</i> or <i>Plasmodium </i>
<i>ovale</i> should receive concomitant therapy with an antimalarial agent active against <i>Plasmodium </i>liver hypnozoites (eg, primaquine).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;20 kg: IM, IV: 3 mg/kg/dose initially, followed by 3 mg/kg/dose at 12 hours and 24 hours; administer additional doses once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37666798','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37666798','lexi-content-ref-WHO.1'])">Ref</a></span>). <b>Note: </b>The FDA-approved dose for this weight group is 2.4 mg/kg/dose based on pharmacokinetic modeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-33605994','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-33605994','lexi-content-ref-manu.1'])">Ref</a></span>); however, some pharmacokinetic modeling indicates that 2.4 mg/kg/dose is inadequate to achieve similar exposure to larger weight groups; consider risks and benefits (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37666798','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37666798','lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: IM, IV: 2.4 mg/kg/dose initially, followed by 2.4 mg/kg/dose at 12 hours and 24 hours. Administer additional doses once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Duration:</i></b>Assess parasite density 4 hours after third dose of artesunate and proceed with therapy based on result as follows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If parasitemia ≤1% and patient able to tolerate oral therapy:</i> Transition to oral; administer a complete oral regimen.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If parasitemia ≤1% and patient </i>
<b>
<i>unable</i></b>
<i> to tolerate oral therapy: </i>Continue with artesunate once daily for up to 6 additional days, followed by a complete oral regimen when patient can tolerate oral therapy.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>If parasitemia &gt;1%:</i> Continue with artesunate once daily until parasitemia ≤1%; transition to oral regimen as soon as parasitemia ≤1% and patient able to tolerate oral therapy; administer a complete oral regimen.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51064932"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18434652','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18434652','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51064933"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18434652','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18434652','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F13321415"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="17088" href="/d/html/17088.html" rel="external">see "Artesunate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="472209b7-e079-42dd-936f-0bec89f10698">Malaria, severe, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, severe, treatment:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Patients with severe malaria due to <i>P. vivax</i> or <i>P. ovale</i> should also receive an antimalarial agent active against the hypnozoite liver stage forms of <i>Plasmodium </i>(eg, primaquine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM (off-label route):</b> 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours. Administer additional doses once daily based on treatment recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3','lexi-content-ref-WHO.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3','lexi-content-ref-WHO.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CDC recommendations: Assess parasite density at least 4 hours after last dose of artesunate and proceed with therapy as follows, based on parasite density:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If parasitemia ≤1% and patient able to tolerate oral therapy:</i> Transition to full treatment course with oral regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If parasitemia ≤1% and patient </i>
<b>
<i>unable</i></b>
<i> to tolerate oral therapy: </i>Continue with artesunate 2.4 mg/kg/dose once daily for up to 6 additional days. After 7 total days of IV therapy, proceed with full treatment course with an oral regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If parasitemia &gt;1%:</i> Continue with artesunate 2.4 mg/kg/dose once daily until parasitemia ≤1% (maximum of 7 days IV treatment). Proceed with full treatment course with an oral regimen as soon as parasitemia ≤1% and patient is able to tolerate oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">WHO recommendations: After at least 24 hours of parenteral treatment, and when patient is able to tolerate oral medication, initiate a full (eg, 3 days) course of oral artemisinin-based combination therapy to complete treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990520"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987826"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F13321359"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hemoglobinuria (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurological signs and symptoms (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, balance impairment, confusion, paresis, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, tremor</p>
<p style="text-indent:-4em;margin-left:4em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Autoimmune hemolytic anemia, hemolysis, hemolytic anemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F13321352"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis) to artesunate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F13321353"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolysis: Postartemisinin delayed hemolysis is characterized by a decrease in Hb with laboratory evidence of hemolysis (eg, decreased haptoglobin, increased lactate dehydrogenase) occurring ≥7 days after initiation of artesunate. Patients with higher parasite density may have a higher likelihood of delayed hemolytic anemia after treatment (CDC 2023). Cases of posttreatment hemolytic anemia severe enough to require transfusion have been reported. A subset of patients has evidence of immune-mediated hemolysis. Monitor patient for 4 weeks after treatment for evidence of hemolytic anemia; consider a direct antiglobulin test to determine if therapy for immune-mediated hemolysis is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity, including anaphylaxis, has been reported. Monitor for signs of hypersensitivity and consider discontinuation of treatment if a reaction occurs.</p></div>
<div class="block foc drugH1Div" id="F44942299"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 110 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 110 mg (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F55717101"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F55830437"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Artesunate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">110 mg (per each): $5,976.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F56057794"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Artesunate is commercially available in the United States. Hospital pharmacies that do not have artesunate in stock when it is needed to treat a patient with severe malaria should call Amivas (1-855-526-4827) to identify the closest distributor of artesunate for a patient emergency or call the emergency line for their drug distributor to request an emergency procurement. More information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmalaria%2Fdiagnosis_treatment%2Fartesunate.html&amp;token=OwnNIPPeGk%2FrbsSIEMq0Iq%2B72Y7%2FKzCOx5oyEMWshHPQDy%2FjeDRG82ICHUayh66%2Bs8MPqpmMKByp3v6Z5pXYF1lchEQxI5AA5yPTwRtFrCs%3D&amp;TOPIC_ID=117986" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html</a>.</p></div>
<div class="block admp drugH1Div" id="F52614503"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Administer by IM injection into the anterior thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer IV over 1 to 2 minutes.</p></div>
<div class="block adm drugH1Div" id="F13321427"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM (off-label route):</b> Administer by IM injection into the anterior thigh (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer via IV bolus slowly over 1 to 2 minutes.</p></div>
<div class="block sts drugH1Div" id="F13321403"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials and diluent at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53570979"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of severe malaria (FDA approved in pediatric patients [age not specified] and adults).</p></div>
<div class="block cyt drugH1Div" id="F28407025"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP2A6 (minor), P-glycoprotein/ABCB1 (minor), UGT1A9, UGT2B7; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F28407022"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Artemether and Lumefantrine.  Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: May increase serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diclofenac (Systemic): May increase serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: May increase serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: May decrease serum concentrations of the active metabolite(s) of Artesunate. Nevirapine may increase the serum concentration of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease serum concentrations of the active metabolite(s) of Artesunate. Nirmatrelvir and Ritonavir may increase the serum concentration of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primaquine: Artesunate may enhance the QTc-prolonging effect of Primaquine. Artesunate may increase the serum concentration of Primaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease serum concentrations of the active metabolite(s) of Artesunate. Ritonavir may increase the serum concentration of Artesunate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: May increase serum concentrations of the active metabolite(s) of Artesunate.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13321350"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">An increased risk of adverse pregnancy outcomes has not been observed following maternal use of artesunate.</p>
<p style="text-indent:0em;margin-top:2em;">Malaria infection during pregnancy may be more severe than in nonpregnant people and has a high risk of maternal and perinatal morbidity and mortality. Malaria infection during pregnancy can lead to miscarriage, premature delivery, low birth weight, congenital infection, and/or perinatal death. Therefore, pregnant patients are advised to avoid travel to malaria-risk areas. When travel is unavoidable, pregnant patients should take precautions to avoid mosquito bites and use effective prophylactic medications (CDC 2023; CDC Yellow Book 2024).</p>
<p style="text-indent:0em;margin-top:2em;">Severe malaria is life-threatening to the mother and fetus. Artesunate is recommended for the treatment of severe malaria during pregnancy regardless of trimester (CDC 2023). Consult current CDC malaria guidelines.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to artesunate is ongoing. Health care providers are encouraged to enroll patients exposed to artesunate during pregnancy in the pregnancy safety study (1-855-526-4827).</p></div>
<div class="block mopp drugH1Div" id="F53570975"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of hypersensitivity reactions; signs and symptoms of hemolytic anemia, hemoglobin, and renal function for 4 weeks after therapy for postartemisinin delayed hemolysis (PADH).</p></div>
<div class="block pha drugH1Div" id="F13321405"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Artesunate, a semisynthetic derivative of artemisinin, is a prodrug that is rapidly metabolized to the active metabolite, dihydroartemisinin (DHA). Artesunate and DHA contain an endoperoxide bridge that is activated by heme iron binding, resulting in oxidative stress, inhibition of protein and nucleic acid synthesis, ultrastructural changes, and a decrease in parasite growth and survival. Both are active against the blood-stage asexual parasites and gametocytes of <i>Plasmodium</i> species (including chloroquine-resistant strains) but <b>not</b> active against the hypnozoite liver stage forms of <i>P. vivax</i> and <i>P. ovale</i>.</p></div>
<div class="block phk drugH1Div" id="F13321407"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Artesunate: 68.5 L; dihydroartemisinin (DHA): 59.7 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~93%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Artesunate (prodrug) is rapidly hydrolyzed by plasma esterases to an active metabolite, DHA. DHA undergoes glucuronidation.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Artesunate: 0.3 hours; DHA: 1.3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: DHA: Adults infected with severe malaria: Within 15 minutes (Newton 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Artesunate: 180 L/hour; DHA: 32.3 L/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13733211"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arinet | Artex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Larinate</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Artegen | Artesun | Gen m</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Malacef</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Plasmotrim</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Artesun</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Absunate | Malari</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Glunate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Artesunate amivas</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aarnet | Afalsi | Altunate | Arkex | Artenate | Arteria | Arteross | Artfin | Artisafe | Artivil | Azunate | Calsunate | Combither at | Corother plus | Dunate | Endomal AT | Falciart | Falcigo | Falcinil | Falciquin | Falcistar | Falcynate | Famal | Fesunate | Gerinate | Glansunate | Hospisunate | Indinate | Laricide | Larinate | Larinate xp | Malnate | Match-Ar | Neosunate | Nisunate | Osonik | Pyralfin a | Rezart-s | Rt net | Rtsun | Rtsunate | Svizunate | Tesunate | Ulteria</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Dunate | Falci care | Falcinil | Gsunate | Larinate | Lysunate | M sunate | Resunate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Rt net</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Dunate</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aretmed | Askasunate | Gsunate | Lever | Plasmotrim</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Artesun campus | Malacef</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Artesun</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arcenate | Gen m | Hi sunate | Misonate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Astir | Larinate</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Gsunate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Plasmotrim-50</span>;</li>
<li>
<span class="countryCode">(TZ)</span> <span class="country">Tanzania, United Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arinate</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Malealth</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Artesun | Artesunate 60mg | Falci care | Haripil | Larinate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Garsun</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Arinate | Artesun | Falcinil | Gsunate</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Artemax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Artesunate.2">
<a name="Artesunate.2"></a>Artesunate [prescribing information]. Wilmington, DE: Amivas Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Artesunate.1">
<a name="Artesunate.1"></a>Artesunate [prescribing information]. Wilmington, DE: Amivas Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8536555">
<a name="8536555"></a>Barradell LB and Fitton A, “Artesunate: A Review of Its Pharmacology and therapeutic Efficacy in the Treatment of Malaria,” <i>Drugs</i>, 1995, 50(4):714-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/8536555/pubmed" id="8536555" target="_blank">8536555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21785506">
<a name="21785506"></a>Callender DM and Hsue G, “Artesunate: Investigational Drug for the Treatment of Severe Falciparum Malaria in Hawai'i,” <i>Hawaii Medical J</i>, 2011, 70(4):77-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/21785506/pubmed" id="21785506" target="_blank">21785506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.4">
<a name="CDC.4"></a>Centers for Disease Control and Prevention (CDC). <i>CDC Yellow Book 2024: Health Information for International Travel</i>. Oxford University Press; 2023. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. Intravenous artesunate for treatment of severe malaria in the United States. <a href="https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html" target="_blank">http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html</a>. Accessed November 21, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention. Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated May 29, 2020. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.3">
<a name="CDC.3"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated June 28, 2023. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11120963">
<a name="11120963"></a>Davis TM, Phuong HL, Ilett KF, et al, “Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria,” <i>Antimicrob Agents Chemother</i>, 2001, 45(1):181-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/11120963/pubmed" id="11120963" target="_blank">11120963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10748910">
<a name="10748910"></a>De Clercq D, Vercruysse J, Vérle P, et al, “Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal,” <i>Trans R Soc Trop Med Hyg</i>, 2000, 94 (1):90–1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/10748910/pubmed" id="10748910" target="_blank">10748910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16125588">
<a name="16125588"></a>Dondorp A, Nosten F, Stepniewska K, et al, “Artesunate versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial,” <i>Lancet</i>, 2005, 366(9487):717-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/16125588/pubmed" id="16125588" target="_blank">16125588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15889385">
<a name="15889385"></a>Franco-Paredes C, Dismukes R, Nicolls D, et al, “Neurotoxicity Due to Antimalarial Therapy Associated With Misdiagnosis of Malaria,” <i>Clin Infect Dis</i>, 2005, 40(11):1710-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/15889385/pubmed" id="15889385" target="_blank">15889385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18444813">
<a name="18444813"></a>Gasasira AF, Kamya MR, Achan J, et al, “High Risk of Neutropenia in HIV-infected Children Following Treatment With Artesunate Plus Amodiaquine for Uncomplicated Malaria in Uganda,” <i>Clin Infect Dis</i>, 2008, 46(7), 985-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/18444813/pubmed" id="18444813" target="_blank">18444813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37666798">
<a name="37666798"></a>Haghiri A, Price DJ, Fitzpatrick P, et al. Evidence based optimal dosing of intravenous artesunate in children with severe falciparum malaria. <i>Clin Pharmacol Ther</i>. 2023;114(6):1304-1312. doi:10.1002/cpt.3041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/37666798/pubmed" id="37666798" target="_blank">37666798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15257799">
<a name="15257799"></a>Inyang-Etoh PC, Ejezie GC, Useh MF, et al, “Efficacy of Artesunate in the Treatment of Urinary Schistosomiasis, in an Endemic Community in Nigeria,” <i>Ann Trop Med Parasitol</i>, 2004, 98(5):491-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/15257799/pubmed" id="15257799" target="_blank">15257799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jansen.1">
<a name="Jansen.1"></a>Jansen FH, Jansen-Luts A, Ameye C, Penali L. Is artesunate or its active metabolite dihydroartemisinin being excreted in the milk of lactating mothers? <i>Am J Trop Med Hyg</i>. 2006;75(5)(suppl):S158.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33605994">
<a name="33605994"></a>Kitabi E, Bensman TJ, Earp JC, et al. Effect of body weight and age on the pharmacokinetics of dihydroartemisinin: Food and Drug Administration basis for dose determination of artesunate for injection in pediatric patients with severe malaria. <i>Clin Infect Dis</i>. 2021;73(5):903-906. doi:10.1093/cid/ciab149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/33605994/pubmed" id="33605994" target="_blank">33605994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19815876">
<a name="19815876"></a>Li Q, Cantilena LR, Leary KH, et al, “Pharmacokinetic Profiles of Artesunate After Single Intravenous Doses at 0.5, 1, 2, 4, and 8 mg/kg in Healthy Volunteers: A Phase I Study,” <i>Am J Trop Med Hyg</i>, 2009, 81(4):615-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/19815876/pubmed" id="19815876" target="_blank">19815876</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18636509">
<a name="18636509"></a>Li Q, Si Y, Smith KS, et al, “Embryotoxicity of Artesunate in Animal Species Related to Drug Tissue Distribution and Toxicokinetic Profiles,” <i>Birth Defects Res B Dev Reprod Toxicol</i>, 2008, 83(4):435-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/18636509/pubmed" id="18636509" target="_blank">18636509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19141850">
<a name="19141850"></a>Maude RJ, Plewes K, Faiz MA, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? <i>Am J Trop Med Hyg</i>. 2009;80:126-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/19141850/pubmed" id="19141850" target="_blank">19141850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9132599">
<a name="9132599"></a>Miller LG and Panosian CB, “Ataxia and Slurred Speech After Artesunate Treatment for Falciparum Malaria,” <i>N Engl J Med</i>, 1997, 336(18):1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/9132599/pubmed" id="9132599" target="_blank">9132599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17089111">
<a name="17089111"></a>Newton PN, Barnes KI, Smith PJ, et al, “The Pharmacokinetics of Intravenous Artesunate in Adults With Severe Falciparum Malaria,” <i>Eur J Clin Pharmacol</i>, 2006, 62(12):1003-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/17089111/pubmed" id="17089111" target="_blank">17089111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18444814">
<a name="18444814"></a>Olliaro P, “Disease and Drug Interactions: Treating Malaria With Artesunate Plus Amodiaquine in Patients Also Receiving Treatment for Concomitant HIV Infection,” <i>Clin Infect Dis</i>, 2008, 46(7):992-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/18444814/pubmed" id="18444814" target="_blank">18444814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18434652">
<a name="18434652"></a>Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. <i>N Engl J Med</i>. 2008;358(17):1829-1836.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/18434652/pubmed" id="18434652" target="_blank">18434652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18419454">
<a name="18419454"></a>Shapira MY, Resnick IB, Chou S, et al, “Artesunate as a Potent Antiviral Agent in a Patient With Late Drug-Resistant Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation,” <i>Clin Infect Dis</i>, 2008, 46(9):1455-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/18419454/pubmed" id="18419454" target="_blank">18419454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2015">
<a name="WHO.2015"></a>World Health Organization. Guidelines for the treatment of malaria, third edition. 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed June 15, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO guidelines for malaria (2023). https://www.who.int/publications/i/item/guidelines-for-malaria. Published March 14, 2023. Accessed July 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21529383">
<a name="21529383"></a>Zoller T, Junghanss T, Kapaun A, et al, “Intravenous Artesunate for Severe Malaria in Travelers, Europe,” <i>Emerg Infect Dis</i>, 17(5):771-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/artesunate-pediatric-drug-information/abstract-text/21529383/pubmed" id="21529383" target="_blank">21529383</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 117986 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
